Diabetes

253-LB: Effect of Combined Low Dose IL-2 plus Polyclonal Tregs in Type 1 Diabetes Patients.

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes.

Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes.

Therapeutic window of interleukin-2 for autoimmune diseases.

Therapeutic window of interleukin-2 for autoimmune diseases.

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.

Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function.

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.

Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function.

Pages